Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.
Natera, Inc. (NASDAQ: NTRA) is a diagnostic and research company in the medical laboratories industry, focused on cell-free DNA testing and precision medicine in oncology, women’s health, and organ health. The Natera news feed on Stock Titan highlights company announcements, clinical data readouts, collaborations, and financial updates that reflect how its testing platforms are used in practice and research.
Recent news has featured advances in molecular residual disease (MRD) testing with Signatera, including new multi-modal AI models that integrate longitudinal circulating tumor DNA, clinical data, digital pathology, and tumor sequencing to refine recurrence risk assessment and outcomes prediction. Natera also reports on large clinical studies and trial analyses in colorectal cancer and breast cancer, where Signatera is used to evaluate MRD, predict treatment response, and support risk stratification.
In women’s health, news items include the launch and validation of Fetal Focus, a single-gene non-invasive prenatal test that uses cell-free DNA from maternal blood to assess inherited conditions when partner testing is not available, as well as updates related to the broader prenatal and carrier screening portfolio. Organ health news may cover the use of Natera’s Prospera test in transplant rejection assessment and related research.
Investors and clinicians can also follow Natera’s announcements about AI collaborations, such as its work with NVIDIA to scale multimodal AI foundation models, and corporate updates including preliminary financial results and participation in healthcare conferences. For those tracking NTRA, this news page provides a centralized view of developments across oncology, women’s health, organ health, and AI-enabled diagnostics.
Natera, Inc. (NASDAQ: NTRA) announced the receipt of the CE mark for its Signatera test, a personalized ctDNA assay designed for molecular residual disease (MRD) assessment in cancer patients. This milestone allows Natera to distribute Signatera across Europe, supporting patient management and clinical research. The test has been validated in multiple cancer types and represents an advancement in cancer care, particularly in monitoring treatment effectiveness. With 3.7 million new cancer cases annually in Europe, the CE mark expands Natera's global reach in personalized cancer therapy.
Natera, Inc. (NASDAQ: NTRA) announced on August 18, 2020, that the American College of Obstetrics and Gynecology (ACOG) and Society of Maternal Fetal Medicine (SMFM) have updated their guidelines to recommend non-invasive prenatal testing (NIPT) for aneuploidy screening for all patients, irrespective of age. The guidelines recognize cfDNA testing's sensitivity and its applicability in twin pregnancies. The updated recommendation is anticipated to enhance NIPT's coverage and usage. Natera has a robust clinical backing, evidenced by 22 peer-reviewed publications and the SMART study, which aims to further validate NIPT's effectiveness.
Natera, Inc. (NASDAQ: NTRA), a leader in cell-free DNA testing, has filed a lawsuit against ArcherDX, Inc. for the infringement of its U.S. Patent No. 10,731,220, issued on August 4, 2020. The lawsuit, filed in the U.S. District Court of Delaware, alleges that ArcherDX's oncology products violate Natera's patented methods related to DNA testing. This follows a prior suit filed against ArcherDX in January 2020 regarding four additional patents. Natera seeks both monetary damages and injunctive relief for these infringements.
Natera, Inc. (NASDAQ: NTRA) reported robust Q2 2020 results, processing approximately 234,100 tests, a 21% increase from Q2 2019. Total revenues reached $86.5 million, up from $74.4 million year-over-year. Gross profit rose to $39.5 million, achieving a 46% gross margin. However, the company faced an operating loss of $51.6 million compared to $28.6 million the previous year. Natera anticipates total 2020 revenues between $345 million and $365 million, with a projected cash burn of $125 million to $155 million.
Natera, Inc. (NASDAQ: NTRA) announced a validation of its Signatera™ circulating tumor DNA (ctDNA) technology in a study published in Nature Cancer. The research shows Signatera's effectiveness in assessing tumor response to immunotherapy across 25 solid cancer types. Key findings include ctDNA detection in 98% of cases before treatment and the ability to predict treatment non-response with 100% accuracy after just 6 weeks. The study highlights the clinical utility of ctDNA-based surveillance to distinguish true disease progression from pseudo-progression, addressing an unmet clinical need.
Natera, a leader in cell-free DNA testing, will announce its Q2 2020 financial results on August 5, 2020, after market close. A conference call is scheduled for 1:30 p.m. PT to discuss the results and future outlook. Natera's labs are certified under CLIA, providing essential genetic testing focused on women's health, oncology, and organ health. Investors can access a replay of the webcast at Natera's investor relations website.
Summary not available.
Natera, a leader in cell-free DNA testing, has expanded its laboratory facility in Austin, Texas, increasing its test processing capacity. The new 70,000 square foot facility features advanced automated equipment, which is expected to lower costs and improve operational continuity. Natera targets significant growth in markets exceeding a $25 billion dollar opportunity, having processed over three million medical tests to date. This expansion positions Natera to better serve patients and capitalize on future market demands.
Natera, Inc. (NASDAQ: NTRA) has announced the initiation of patient enrollment in two clinical trials: CIRCULATE-Japan and BESPOKE CRC. The CIRCULATE-Japan trial is a multi-center study with 2,500 participants focused on ctDNA-guided treatment strategies for resectable colorectal cancer (CRC) in Japan. Similarly, BESPOKE CRC aims to enroll over 1,000 patients, assessing the impact of blood-based testing for early relapse detection. Both trials highlight the growing interest and potential of Signatera technology, which may improve treatment outcomes for CRC patients globally.
Natera, Inc. (NASDAQ: NTRA) has filed a patent infringement lawsuit against Progenity, Inc. in the U.S. District Court for the Western District of Texas. The suit claims that Progenity's non-invasive prenatal test infringes on six patents held by Natera. These include U.S. Patents 9,228,234; 9,424,392; 10,227,652; 10,240,202; 10,266,893; and 10,522,242. Natera is seeking both injunctive relief and monetary damages.
FAQ
What is the current stock price of Natera (NTRA)?
What is the market cap of Natera (NTRA)?
